Bone marrow for the brain?

Experimental Neurology

Volumn 199, Issue 1, 2006, Pages 16-19

  Brass, Lawrence M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW; BRAIN; BRAIN INJURY; CELL IMMORTALIZATION; CELL TRANSPLANTATION; CLINICAL TRIAL; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HEART STROKE VOLUME; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPERFUSION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE; UMBILICAL CORD BLOOD; VASCULAR DISEASE; ANIMAL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BRAIN ISCHEMIA; CYTOLOGY; METHODOLOGY; NERVE CELL; NOTE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; BRAIN; BRAIN ISCHEMIA; HUMANS; NEURONS;

EID: 33745195177     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.03.009     Document Type: Note

References (36)

1. Brass L.M., and Alter M. Clinical trial design for cerebrovascular disorders. In: Fisher M. (Ed). Stroke Therapy (1995), Butterworth-Heinemann, Newton 135-170
2. Chopp M., and Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol. 1 (2002) 92-100
3. Committee on Guidelines for Human Embryonic Stem Cell Research. Guidelines for Human Embryonic Stem Cell Research (2005), The National Academies Press, Washington, DC
4. Coplin W.M., Cochran M.S., Levine S.R., et al. Stroke after bone marrow transplantation: frequency, aetiology, and outcome. Brain 124 (2001) 1043-1051
5. Donnan G.A., and Davis S.M. Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol. 1 (2002) 417-425
6. Dyker A.G., and Lees K.R. Duration of neuroprotective treatment for ischemic stroke. Stroke 29 (1998) 535-542
7. Fukuda S., and del Zoppo G.J. Models of focal cerebral ischemia in the nonprimate human. ILAR J. 44 (2003) 96-104
8. Gilman S. Time course and outcome of recovery from stroke: relevance to stem cell treatment. Exp. Neurol. 199 1 (2006) 37-41
9. Gilman S. Pharmacologic management of ischemic stroke: relevance to stem cell therapy. Exp. Neurol. 199 1 (2006) 28-36
10. Gladstone D.J., Black S.E., Hakin A.M., et al. Toward wisdom from failure: lessons from neuroprotection stroke trials and new therapeutic directions. Stroke 33 (2002) 2123-2136
11. Honma T., Honmou O., Iihoshi S., et al. Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemic model in adult rat. Exp. Neurol. 199 1 (2006) 56-66
12. Jiang W., Gu W., Brännström T., et al. Cortical neurogenesis in adult rats after transient middle cerebral artery occlusion. Stroke 32 (2001) 1201-1207
13. Johnston S.C., Gress D.R., Browner W.S., et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284 (2000) 2901-2906
14. Johnston K.C., Wagner D.P., Haley Jr. C., et al. Combined clinical and imaging information as an early stroke outcome measure. Stroke 33 (2002) 466-472
15. Kang D.W., Latour L.L., Chalela J.A., et al. Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann. Neurol. 54 (2003) 66-74
16. Katzan I.L., Furlan A.J., Lloyd L.E., et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283 (2000) 1151-1158
17. Kidwell C.S., Liebeskind D.S., Starkman S., et al. Trends in acute ischemic stroke trials through the 20th century. Stroke 32 (2001) 1349-1359
18. Lees K.R., hankey G.J., and Hacke W. Design of future acute-stroke treatment trials. Lancet Neurol. 2 (2003) 54-61
19. Li Y., Chen J., Chen X.G., et al. Human marrow stromal cell therapy for stroke in rate: neurotrophins and functional recovery. Neurology 59 (2002) 514-523
20. McFarland H.F., Barkhof F., Antel J., et al. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler. 8 (2002) 40-51
21. Newman M.B., Willing A.E., Manresa J.J., Sanberg C.D., and Sanberg P.R. Cytokines produced by cultured human umbilical cord blood (HUCB) cells: implications for brain repair. Exp. Neurol. 199 1 (2006) 201-208
22. Ourednik J., Ourednik V., Lynch W.P., Schachner M., and Snyder E.Y. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat. Biotech. 20 (2002) 1103-1110
23. Park K.I., Hack M.A., Ourednik J., Yandava B., Flax J.D., Stieg P.E., Gullans S., Jensen F.E., Sidman R.L., Ourednik V., and Snyder E.Y. Acute injury directs the migration, proliferation, and the differentiation of solid organ stem cells: Evidence from the effect of hypoxia--ischemia in the CNS on clonal "reporter" neural stem cells. Exp. Neurol. 199 1 (2006) 156-178
24. Park K.I., Himes B.T., Stieg P.E., Tessler A., Fisher I., and Snyder E.Y. Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic--ischemic brain injury. Exp. Neurol. 199 1 (2006) 179-190
25. Pollock K., Stroemer P., Patel S., Stevanato L., Hope A., Miljan E., Dong Z., Hodges H., Price J., and Sinden J.D. A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp. Neurol. 199 1 (2006) 143-155
26. Rothwell P.M., Giles M.F., Flossmann E., et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischemic attack. Lancet 365 (2005) 1-8
27. Savitz S.I., Rosenbaum D.M., Dinsmore J.H., et al. Cell transplantation for stroke. Ann. Neurol. 52 (2002) 266-275
28. Selnes O.A., and McKhann G.M. Neurocognitive complications after coronary artery bypass surgery. Ann. Neurol. 57 (2005) 615-621
29. Sostak P., Padovan C.S., Yousry T.A., et al. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 60 (2003) 842-848
30. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
31. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32 (2001) 1598-1606
32. Sudhir K. Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor of cardiovascular disease. J. Clin. Endocrinol. Metab. 90 (2005) 3100-3105
33. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333 (1995) 1581-1587
34. Vendrame M., Gemma C., Pennypacker K.R., Bickford P.C., Davis-Sanberg C.C., Sanberg P.R., and Willing A.E. Cord blood rescues stroke-induced changes in splenocyte phenotype and function. Exp. Neurol. 199 1 (2006) 191-200
35. Weir C.J., Kaste M., Lees K.R., et al. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke 35 (2004) 2111-2116
36. Yadav J.S., Wholey M.H., Kuntz R.E., et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. 351 (2004) 1493-1501